Healthcare professionals (HCPs) are not only worried about how they will get through COVID-19, they’re also concerned about the long-term well-being of their patients, according to a new survey published today by Fingerpaint.
The Fingerpaint COVID-19 HCP Survey showed that 59% percent of HCPs were worried about their patients not being diagnosed in a timely manner, and 58% believe their patients will not be able to obtain previously prescribed in-office/outpatient care. More than half of those surveyed (53%) don’t think their patients have the ability to utilize telemedicine and will not be able to refill their medications.
They believe the pandemic will have a long-term impact on their practice. In fact, 59% of them believe they won’t feel more hopeful about the current COVID-19 situation for at least 2 to 6 months.
“As brands refine their marketing efforts, it is important to have a deep understanding of what’s keeping HCPs awake at night and how this pandemic is impacting them and their patients,” said Michelle Petroff, head of Fingerpaint’s Conshohocken, PA, office. “Many of the HCPs reached in this survey are not just worried about the short-term issues, but are looking for long-term solutions.”
There was positive news in the survey. While overall 66% of HCPs reported feeling anxious about COVID-19 as it applies to their practice, only 5% went as far as saying that they feel defeated.
The survey link was sent in an email to about 16,000 contacts. Respondents were screened to ensure their status as healthcare professionals who reside in the United States, were board-certified in their specialty, and had a minimum of 4 and maximum of 40 years’ practice experience. A total of 116 healthcare professionals completed the online survey during the week of March, 2020.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.